Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2014

View Archived Issues

Phase I results presented for the new PET tracer [18F]-FSPG

Foamix begins phase II trial of FDX-104 to prevent EGFR inhibitor-induced rash

Merck Serono, the ICR and the Wellcome Trust collaborate to discover tankyrase inhibitors

NanoString Technologies and Brigham and Women's Hospital collaborate to develop cancer diagnostics

MicroRNA identified as a biomarker target for MS

Interim phase II results for squalamine lactate plus ranibizumab in neovascular AMD

SNP signature linked to response to glatiramer in patients with MS

AbbVie discloses novel CDK9/cyclin-T1 inhibitors for cancer

BNN-93, a novel neuroprotective ocular solution

Researchers at Oncodesign patent novel RIP-2 inhibitors

Sanofi divulges new SGK1 inhibitors

Researchers in London prepare novel SSAO inhibitors for COPD and other disorders

A team of scientists at Novartis synthesize new complement C5 convertase inhibitors

FDA grants orphan drug status to DNX-2401 for glioma

MacroGenics begins phase I study of MGD-007

FDA grants fast track designation to NurOwn for ALS

DiscoveryBioMed receives grant for ADPKD drug development

StemCells begins phase II trial of HuCNS-SC in cervical SCI

NIAID awards grant to Hampton University for work in infectious disease

Bristol-Myers Squibb withdraws NDA for asunaprevir

Generex Biotechnology explores opportunities for Antigen Express technology against Ebola

Orphazyme prepares phase II/III trial of arimoclomol in Niemann-Pick disease type C

Lead Discovery Center and UiT The Arctic University of Norway seek drugs in arctic sea organisms

Second Genome partners with Mayo Clinic to develop microbiome therapeutics

Cardio3 BioSciences gains preferred access to Mayo Clinic technologies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...